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Lead poisoning is a complex disorder affecting
many organs in the body, including develop-
ing red blood cells, the kidneys, and the
nervous system. Young children are most sus-
ceptible to the toxic effects of lead. Major
concerns are the cognitive and neurobehav-
ioral deﬁcits resulting from lead exposure lev-
els that were previously considered safe. High
levels of exposure can cause encephalopathy
and death [Agency for Toxic Substances and
Disease Registry (ATSDR) 1999].
Lead deposition in the body consists of
three major pools: blood, bone, and soft tis-
sues (Rabinowitz et al. 1976). The blood pool
accounts for only 2% of the total body bur-
den, unless there is an acute exposure, but is a
rapidly exchangeable component. The bone
pool contains > 95% of the total body bur-
den, where it may be mobilized and con-
tribute to the blood lead level (BLL) in
previously exposed persons. Differences in
lead accumulation in various bone types have
been reported. Tibia concentrations differ
from those observed in the patella. The corti-
cal bone of the tibia represents a long-term
storage depot with an elimination half-life for
lead in excess of a decade. In contrast, the
more dynamic trabecular bone of the patella
exhibits a shorter half-life (Rabinowitz et al.
1976).The remainder of the total body load is
distributed in an intermediate pool of soft
tissues, skin, and muscle. Elimination half-
lives for lead are estimated at 30–40 days in
blood and up to 20 years or longer in bone
(Marcus 1985a, 1985b). Lead is eliminated
mainly in the urine.
Lead is a potent inhibitor of δ-amino-
levulinic acid dehydratase (ALAD), copropor-
phyrinogen oxidase, and ferrochelatase,
enzymes that catalyze the second, sixth, and
ﬁnal steps, respectively, in the biosynthesis of
heme (Onalaja and Claudio 2000; Warren
et al. 1998). Because the metal has the greatest
effect on ALAD, measurement of ALAD
activity can be used as a marker of effect of
lead exposure (Chisolm et al. 1985). ALAD,
an octameric zinc-containing enzyme, cat-
alyzes the condensation of two molecules of
5-aminolevulinic acid (ALA) into one mole-
cule of monopyrrole porphobilinogen (PBG).
Inhibition of ALAD activity produces
increased urinary excretion of ALA (Warren
et al. 1998).
Lead displaces zinc from the enzyme’s
active site, and the inactivation of ALAD has
been implicated in the pathogenesis of lead
poisoning. The resulting accumulation of its
substrate, ALA, has been shown to have a
neuropathogenic effect, probably by acting as
a γ-aminobutyric acid (GABA) receptor
agonist in the nervous system (Brennan and
Cantrill 1979).
Human ALAD, encoded by a single gene
localized to the chromosome 9q34 region, is a
polymorphic enzyme with two alleles, ALAD1
and ALAD2 [Single Nucleotide Polymorphism
database (dbSNP) ID: rs1800435; http://
www.ncbi.nlm.nih.gov/SNP/index.html],
which are co-dominantly expressed (Battistuzzi
et al. 1981). The difference between the two
alleles lies in a single G→C transversion muta-
tion of nucleotide 177 in ALAD2; the
allozyme resulting from the ALAD2 allele con-
tains the substitution of a neutral asparagine
for a positively charged lysine at residue 59
(Wetmur et al. 1991b). Three differently
charge allozymes, ALAD1-1, 1-2, and 2-2,
result from the expression of the ALAD1 and
ALAD2 genes. In several white populations,
the frequencies of the ALAD1 and ALAD2
genes have been estimated to be 0.9 and 0.1,
respectively. Asian and African populations
have lower frequencies of the ALAD2 allele
(Kelada et al. 2001).
Several epidemiologic studies have
attempted to correlate the ALAD allelic varia-
tions with a differential susceptibility to lead
poisoning. The biologic plausibility for a dif-
ferential role of the two alleles lies in the fact
that the lysine substitution at residue 59
changes the electrical charge of the enzyme
(Battistuzzi et al. 1981); the more electroneg-
ative ALAD2 enzyme may thus have a higher
affinity/stability for the lead cation than
ALAD1 (Wetmur et al. 1991b). This could
result in an alteration of lead toxicokinetics
and susceptibility to lead toxicity. The first
studies comparing BLL and ALAD polymor-
phism were conducted on a chronically
exposed population of 202 male lead workers
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BACKGROUND: Lead poisoning affects many organs in the body. Lead inhibits δ-aminolevulinic acid
dehydratase (ALAD), an enzyme with two co-dominantly expressed alleles, ALAD1 and ALAD2. 
OBJECTIVE: Our meta-analysis studied the effects of the ALAD polymorphism on a) blood and
bone lead levels and b) indicators of target organ toxicity. 
DATA SOURCE: We included studies reporting one or more of the following by individuals with geno-
types ALAD1-1 and ALAD1-2/2-2: blood lead level (BLL), tibia or trabecular lead level, zinc proto-
porphyrin (ZPP), hemoglobin, serum creatinine, blood urea nitrogen (BUN), dimercaptosuccinic
acid–chelatable lead, or blood pressure.
DATA EXTRACTION: Sample sizes, means, and standard deviations were extracted for the genotype
groups.
DATA SYNTHESIS: There was a statistically significant association between ALAD2 carriers and
higher BLL in lead-exposed workers (weighted mean differences of 1.93 µg/dL). There was no asso-
ciation with ALAD carrier status among environmentally exposed adults with BLLs < 10 µg/dL.
ALAD2 carriers were potentially protected against adverse hemapoietic effects (ZPP and hemo-
globin levels), perhaps because of decreased lead bioavailability to heme pathway enzymes. 
CONCLUSION: Carriers of the ALAD2 allele had higher BLLs than those who were ALAD1 homo-
zygous and higher hemoglobin and lower ZPP, and the latter seems to be inversely related to BLL.
Effects on other organs were not well delineated, partly because of the small number of subjects
studied and potential modifications caused by other proteins in target tissues or by other poly-
morphic genes.
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Researchin a German factory (Ziemsen et al. 1986),
and an environmentally exposed population
of 1,051 children with elevated free erythro-
cyte protoporphyrin (Astrin et al. 1987).
These studies showed that individuals carry-
ing one or two copies of the ALAD2 allele
exhibited higher BLLs than homozygous indi-
viduals with only the ALAD1 allele. These
findings led to the suggestion that ALAD2
may be a determinant for increased suscepti-
bility to lead toxicity (Wetmur et al. 1991a).
However, some studies have reported either
no difference among individuals homozygous
for ALAD1 relative to individuals carrying the
ALAD2 allele, or the differences among the
two groups were not statistically significant.
The extreme variability in the published data
is due to several factors: relatively small num-
bers of subjects, different frequencies of the
ALAD2 allele in various populations, and dif-
ferent levels of lead exposure as determined by
BLLs in the populations studied. We used a
series of meta-analyses to quantify the effects
of this genetic polymorphism and to under-
stand lead toxicokinetics.
Methods
Study selection. MEDLINE (National Library
of Medicine 2006) and Web of Science
(Thomson Scientific 2006) databases were
searched to January 2006 for English-language
publications of observational studies. The cita-
tions in the articles identified were also
searched to ﬁnd other potentially eligible stud-
ies. Common text words and Medical Subject
Headings (MeSH) related to lead poisoning,
gene polymorphism, and ALAD were used.
No attempt was made to contact the authors
of any of the articles, except to resolve discrep-
ancies in the reported values. 
We required that two a priori criteria be
met for inclusion in the meta-analysis: a) sam-
ple sizes, means, and SDs were either reported
or could be determined for the ALAD1-1 and
ALAD1-2/2-2 genotypes; and b) combined
with one or more of the following measures—
BLL, tibia lead level, trabecular (patella or cal-
caneus) lead level, zinc protoporphyrin (ZPP),
hemoglobin, serum creatinine, dimercaptosuc-
cinic acid–chelatable lead, and systolic or dias-
tolic blood pressure. When multiple studies
used the same cohort of subjects, the ﬁrst pub-
lication that reported the values of the vari-
ables of interest was included. 
Data extraction. Sample sizes, means, and
SDs according to genotype (homozygous
ALAD1-1 and ALAD2-2 and heterozygous
ALAD1-2) were extracted independently by
two authors (F.S and D.M.). Wu et al.
(2004) reported data in groups of workers
subjected to high and low lead exposures. We
mathematically combined the data of the two
groups to extract the means for all exposed
workers according to the genotype. The
pooled estimate of the variance from two
independent samples was used to extract the
SDs according to genotype. Therefore, only
one effect size was entered in the model. The
data from each study were entered twice to
minimize data-entry errors. 
Statistical analysis. The data were analyzed
using Stata software version 7 (StataCorp.,
College Station, TX, USA). In each study the
size of the effect was calculated by the differ-
ence between the means of the ALAD1-2/2-2
and the ALAD1-1 groups. Each mean differ-
ence was weighted according to the inverse of
its variance, and the average was taken
[weighted mean difference (WMD)]. To com-
bine data from studies in which the same out-
come was measured by different scales (serum
creatinine), or when the outcome value was
measured by different methods (bone lead,
ZPP), the mean difference was standardized by
dividing by the within-group SD; the results
were then weighted and the average, or stan-
dardized mean difference (SMD), taken. The
WMD or SMD in each study was pooled
using a random-effects model. Results are
given with 95% confidence intervals (CIs).
Between-study heterogeneity in the results of
the studies was assessed using a chi-square 
test and the I 2 measure of inconsistency.
Signiﬁcant heterogeneity was deﬁned as a chi-
square test p-value < 0.1. I 2 takes values
between 0% and 100% with higher values
denoting greater degree of heterogeneity (I2 =
0–25%: no heterogeneity; I2 = 25–50%: mod-
erate heterogeneity; I2 = 50–75%: large hetero-
geneity; I2 = 75–100%: extreme heterogeneity)
(Higgins et al. 2003). Furthermore, to examine
between-study heterogeneity, we used a priori
stratiﬁed analyses including the study design
(occupational and environmental studies) and
age status (children and adults) and presence of
Hardy-Weinberg equilibrium (HWE).
Publication bias was assessed using the meth-
ods proposed by Begg and Mazumdar(1994)
and by Egger et al. (1997). All p-values are
two-tailed.
Results
The search procedure yielded 45 references
that were retrieved for additional information
(Figure 1). We initially excluded 4 review
papers, 5 non-English research articles, and 2
articles that reported data on different variant
of the ALAD2 polymorphism. Of the remain-
ing 34 articles, 7 did not have relevant data for
effect size calculation. Moreover, the corre-
sponding author of a study of environmentally
exposed children (Shen et al. 2001) was con-
tacted twice by monthly e-mail to resolve
some discrepancy in their reported study.
Three months after failing to receive an
answer, we decided to exclude the study.
Therefore, 24 studies were included in the
meta-analysis (Alexander et al. 1998; Astrin
et al. 1987; Duydu and Suzen 2003; Fleming
et al. 1998; Hsieh et al. 2000; Hu et al. 2001;
Kim et al. 2004; Lee BK et al. 2001; Lee SS
et al. 2001; Perez-Bravo et al. 2004; Sakai
et al. 2000; Schwartz et al. 1995, 1997a,
1997b, 2000; Sithisarankul et al.1997; Smith
et al. 1995; Suzen et al. 2003; Theppeang
et al. 2004; Weaver et al. 2003; Wetmur et al.
1991a; Wu et al. 2003, 2004; Ziemsen et al.
1986), and of these, 11 were multiple publica-
tions that often had other different outcomes
of interest. When we found a discrepancy in
the reported studies, the authors were con-
tacted and the corrected data were used.
Table 1 characterizes the studies that did meet
criteria for inclusion.
ALAD polymorphism and blood lead level.
Nine occupational studies (Alexander et al.
1998; Fleming et al. 1998; Kim et al. 2004;
Sakai et al. 2000; Schwartz et al. 1995, 2000;
Suzen et al. 2003; Wetmur et al. 1991a; Wu
et al. 2004) were included in our analysis, and
5 environmental exposure studies of which 3
were conducted among adults (Smith et al.
1995; Hsieh et al. 2000; Wu et al. 2003) and
2 among children (Perez-Bravo et al. 2004;
Wetmur et al. 1991a). Thus, a total of
14 studies were included in our analysis of
blood lead level and ALAD polymorphism.
Each of the studies was rechecked for HWE.
We did not find HWE in the study by
Wetmur et al. (1991a) that presented separate
data on previously reported studies of occupa-
tional exposure in adults (Ziemsen et al. 1986)
and environmental exposure in children
(Astrin et al. 1987). The absence of HWE is
most likely because of ethnicities of the popu-
lations: the occupational study comprised
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Figure 1. Flow chart of study selection.
Studies included (n = 24)
Multiple publications with
blood lead levels, but other
outcomes of interest: 11
Potentially relevant articles
identified through MEDLINE
up to January 2006 (n = 45)
Studies excluded (n = 11)
Review papers: 4
Other polymorphisms in ALAD: 2
Non-English research articles: 5
Articles retrieved for
evaluation (n = 34)
Studies excluded (n = 8)
No relevant data for effect size
calculation: 7
Discrepancy in published data: 1workers of German and Turkish origins
(Ziemsen et al. 1986), whereas the study of
children included whites, blacks, Hispanics,
and Asians (Astrin et al. 1987). Table 2 shows
the frequency of the ALAD polymorphism
and the status of the HWE in the studies
analyzed. 
There is evidence that inclusion of stud-
ies that deviate from HWE can affect the
pooled estimate and be potential sources of
heterogeneity across the studies (Trikalinos
et al. 2006). Hence, we conducted pooled
analysis with and without studies that devi-
ated from HWE.
Pooled WMD analysis among the 14
studies, which included a total of 6,672 sub-
jects, 5,861 (87.84%) were homozygous for
ALAD1 and 811 (12.16%) carried the
ALAD2 allele, showed a large heterogeneity
among the studies (χ2
13 = 54.75; p = 0.000;
I2 = 76.3%) (Table 3; Figure 2). In subgroup
analysis (subgroups were deﬁned by the type
of study and by population, that is, occupa-
tionally and environmentally exposed adults
and children), there was no heterogeneity
between occupational studies (I 2 = 0),
between the studies of environmentally
exposed children (I2 = 0), and moderate het-
erogeneity among the studies of environmen-
tally exposed adults (I 2 = 55.2%). After
removal of the studies not in HWE, the over-
all heterogeneity decreased (χ2
11 = 17.92; p =
0.07), and the variation in WMD attributable
to heterogeneity was moderate (I 2 = 38.6%)
(Table 3). Overall, the pooled WMD analysis
indicated that the carriers of ALAD2 allele
had a significantly higher BLL (2.31 μg/dL;
95% CI, 0.93 to 3.70) compared with carriers
homozygous for the ALAD1 allele, a ﬁnding
that was mostly driven by the occupational
studies. Removal of the two studies not in
HWE resulted in a not significantly higher
WMD level of BLL (0.86 μg/dL; 95% CI,
–0.1 to 1.73). There was no evidence of pub-
lication bias according to Begg’s test (p = 1.0,
with continuity correction) and Egger’s test
(p = 0.10). 
Occupational studies. Lead workers car-
rying the ALAD2 allele had higher BLLs
(WMD = 2.56 μg/dL; 95% CI, 1.21 to 3.90),
with the difference being statistically signifi-
cant (p = 0.027) (Figure 3). Analysis of the
studied in HWE (Table 3) resulted in a
decreased but still significant higher WMD
(2.24 μg/dL; 95% CI, 0.85 to 3.62).
Environmental adult studies. By contrast,
the WMD in adults environmentally exposed
to lead was 0.05 μg/dL (95% CI, –0.79 to
0.88), which was not statistically signiﬁcant.
Environmental children studies. Pooled
analysis of the two studies of children showed
a WMD in BLL of 7.34 μg/dL (95% CI, 4.92
to 9.76), with the individuals carrying ALAD2
having significantly higher BLLs (p = 0.00).
However, the data should be viewed cau-
tiously because other than deviation from
HWE, the individuals selected for the study
reported by Wetmur et al. (1991a) had higher
initial clinical evaluations of elevated erythro-
cyte protoporphyrin (FEP) levels thus intro-
ducing potentially serious selection bias in the
study design.
ALAD polymorphism and lead: a meta-analysis
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Table 1. Characteristics of the studies included in the review.
Source Population Gene Variables
Ziemsen et al. 1986a Lead workers ALAD BLL
Astrin et al. 1987a Children ALAD BLL
Wetmur et al. 1991aa Lead workers and children ALAD BLL
Smith et al. 1995  Carpenters ALAD BLL, PBL, SC, SBP, DBP 
Schwartz et al. 1995b Lead workers ALAD BLL, ZPP
Schwartz et al. 1997ab Lead workers ALAD BLL, DMSA, ZPP
Schwartz et al. 1997bb Lead workers ALAD BLL, DMSA, ZPP
Sithisarankul et al. 1997b Lead workers ALAD BLL, ZPP, HB
Alexander et al. 1998  Lead workers ALAD BLL, ZPP
Fleming et al. 1998  Lead workers ALAD BLL, TBL, CBL
Hsieh et al. 2000  General population ALAD BLL, HB
Sakai et al. 2000  Lead workers ALAD BLL, ZPP
Schwartz et al. 2000c Lead workers ALAD, VDR BLL, TBL, DMSA, HB
Lee BK et al. 2001c Lead workers ALAD, VDR BLL, TBL, DMSA, SBP, DBP
Hu et al. 2001d Veterans ALAD BLL, TBL, PBL, DMSA
Lee SS et al. 2001c Lead workers ALAD, VDR BLL, TBL, ZPP, HB
Suzen et al. 2003e Lead workers ALAD BLL
Wu et al. 2003d Veterans  ALAD BLL, TBL, PBL, SC, DBP
Duydu and Suzen 2003e Lead workers ALAD BLL
Weaver et al. 2003c Lead workers ALAD, VDR, eNOS BLL, TBL, SC
Kim et al. 2004  Lead workers ALAD BLL, ZPP, HB
Theppeang et al. 2004  Lead workers ALAD, VDR, eNOS PBL
Wu et al. 2004  Lead workers ALAD BLL, ZPP, HB
Perez-Bravo et al. 2004  Children ALAD BLL, HB
Abbreviations: BLL, blood lead level; BUN, blood urea nitrogen; CBL, calcaneus bone lead; DBP, diastolic blood pressure;
DMSA, DMSA-chelatable lead; HB, hemoglobin; PBL, patella bone lead; SBP, systolic blood pressure; SC, serum creati-
nine; TBL, tibia bone lead; ZPP, zinc protoporphyrin.
aThese studies use the same population data. bThese studies use the same population data. cThese studies use the same
population data. dThese studies use the same population data. eThese studies use the same population data.
Table 2. Frequency of ALAD allele and HWE in the studies analyzed.
Source Total no. ALAD1-1 ALAD1-2 ALAD2-2 ALAD1  (p) ALAD2 (q) HWE
Occupational studies
Wetmur et al. 1991a  203 161 32 10 0.872 0.128 No
Schwartz et al. 1995  307 273 34 0 0.945 0.055 Yes
Alexander et al. 1998  134 114 20 0 0.925 0.075 Yes
Fleming et al. 1998  382 312 67 3 0.904 0.096 Yes
Sakai et al. 2000  192 161 29 2 0.914 0.086 Yes
Schwartz et al. 2000  795 716 79 0 0.950 0.050 Yes
Suzen et al. 2003  71 50 21 0 0.852 0.148 Yes
Kim et al. 2004  1,219 1,106 113 0 0.954 0.046 Yes
Wu et al. 2004  57 42 15 0 0.868 0.132 Yes
Environmental studies, adults
Smith et al. 1995  688 592 94 2 0.929 0.071 Yes
Hsieh et al. 2000  660 630 29 1 0.977 0.023 Yes
Wu et al. 2003  709 595 107 7 0.915 0.085 Yes
Environmental studies, children
Wetmur et al. 1991a  1,278 1,136 129 13 0.939 0.061 No
Perez-Bravo et al. 2004  93 84 8 1 0.946 0.054 Yes
Table 3. Summary effect size of blood lead level in ALAD1-2/2-2 versus ALAD1-1 carriers.
Publication bias 
tests (p-value)
WMD  χ2 test Begg
Population and subgroup analysis No. of studies [µg/dL (95% CI)]  p-value I2 (%) (corrected) Egger
ALL 14 2.31 (0.93 to 3.70)* 0.0 76.3 1.0 0.10
ALL in HWE 12 0.86 (–0.01 to 1.73) 0.07 38.6
Occupational 10 2.56 (1.21 to 3.90)* 0.65 0.0 1.0 0.42
Occupational in HWE 9 2.24 (0.85 to 3.62)* 0.97 0.0
Environmentally exposed adults 3 0.05 (–0.79 to 0.88) 0.11 55.2 1.0 0.32
Environmentally exposed children 2 7.34 (4.92 to 9.76)* 0.57 0.0 1.0 NA
Environmentally exposed children in HWE 1 5.5 (–1.39 to 12.39) NA NA NA NA
NA, not applicable.
*Statistically signiﬁcant, p < 0.05.ALAD polymorphism and heme synthesis.
Zinc protoporphyrin (ZPP). Six published
occupational studies related ZPP to ALAD
polymorphism (Alexander et al. 1998; Kim
et al. 2004; Lee SS et al. 2001; Sakai et al.
2000; Schwartz et al. 1995; Wu et al. 2004).
Because the methods used to measure ZPP
were not uniform, we calculated the SMD.
The overall pooled SMD was –0.09, indicat-
ing that individuals carrying the ALAD 2 allele
had lower ZPP values (Figure 3). However,
the SMD was not statistically significant
(95% CI, –0.22 to 0.03; p = 0.13).
Heterogeneity was not signiﬁcant (χ2
5 = 3.88,
p = 0 .56; I2 = 0.0%), indicating that the stud-
ies were homogeneous. There was no evidence
of publication bias according to Begg’s test
(p =1.0, with continuity correction) and
Egger’s test (p = 0.37).
Hemoglobin. Six published cross-sectional
studies related hemoglobin levels to ALAD
polymorphism: four occupational (Kim et al.
2004; Schwartz et al. 1997a, 2000; Wu et al.
2004), one on environmentally exposed adults
(Hsieh et al. 2000), and one on environmen-
tally exposed children (Perez-Bravo et al.
2004) studies. Individuals carrying ALAD2
had higher hemoglobin measurements
(WMD = 0.18 g/dL; 95% CI, 0.05 to 0.31;
p = 0.007) (Figure 4). However, stratiﬁcation
by study design shows that individuals envi-
ronmentally exposed to lead carrying ALAD2
had a not statistically signiﬁcant higher hemo-
globin measurement (WMD = 0.22 g/dL;
95% CI, –0.20 to 0.63; p = 0.306). Hetero-
geneity was not signiﬁcant (χ2
5= 1.55; p = 0.9;
I2 = 0.0%); the studies are thus homogeneous
and it is appropriate to use the summary
weighted mean. There was no evidence of
publication bias according to Begg’s test (p =
0.45, with continuity correction) and Egger’s
test (p = 0.66). 
ALAD polymorphism and bone compart-
ment. Tibia lead level. Ten studies reported
data on lead levels in tibia bone and ALAD
polymorphism as an outcome measure. Four
studies that relied on previous data sets (Lee
BK et al. 2001; Lee SS et al. 2001; Weaver
et al. 2003; Wu et al. 2003) and two that did
not have data based on the polymorphism
(Bellinger et al. 1994; Weaver et al. 2003)
were excluded, leaving four studies for analy-
sis: two studies involving lead workers
(Fleming et al. 1998; Schwartz et al. 2000)
and two of environmentally exposed adults
(Smith et al. 1995; Wu et al. 2003). Because
the methods used to measure tibia lead levels
were not the same in all studies, the pooled
SMD was calculated. The overall pooled
SMD of –0.07 was not signiﬁcant (95% CI,
0.20 to 0.05) and no signiﬁcant heterogeneity
existed among the studies (I 2 = 0.0%)
(Table 4).
Trabecular (patella and calcaneus) lead
level. Four studies—two occupational studies
(Fleming et al. 1998; Theppeang et al. 2004)
and two environmental studies (Smith et al.
1995; Wu et al. 2003)—were analyzed for dif-
ferences in trabecular lead level and ALAD
polymorphism. The overall pooled SMD of
–003 (95% CI: 0.16, 0.09) was not signiﬁcant
and heterogeneity was absent (I 2 = 0.0%)
(Table 4).
Difference between trabecular and cortical
bone lead level. Two environmental studies
(Hu et al. 2001; Smith et al. 1995) and one
involving lead workers (Fleming et al. 1998)
were analyzed for differences between trabec-
ular (patella and calcaneus) and cortical (tibia)
bone lead levels and ALAD polymorphism.
The overall pooled SMD (SMD = 0.03;
95% CI, 0.21 to 0.26) was not significant,
but there was moderate heterogeneity (I 2 =
50.9%) (Table 4). Overall, these analyses
showed no significant difference between
ALAD genotypes and trabecular and cortical
bone lead concentrations. 
ALAD polymorphism and DMSA test
outcome. Dimercaptosuccinic acid (DMSA) is
a chelating agent used to treat lead intoxica-
tion. Two studies (Schwartz et al. 1997b,
2000) reported chelatable urinary lead after
administration of oral doses of DMSA. The
WMD calculated from these studies showed
that individuals homozygous for ALAD2 had
an average of –21.30 μg of DMSA-chelatable
lead (95% CI, 40.81 to –1.79; p = 0.03)
higher than heterozygous workers (Table 4).
Scinicariello et al.
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Figure 3. Random-effect SMD in ZPP values between ALAD1-2/2-2 and ALAD1-1 carriers. 
Study Weight (%) SMD (95% CI)
SMD
0.09 (–0.26 to 0.45)
–0.24 (–0.71 to 0.24)
–0.19 (–0.58 to 0.19)
0.02 (–0.21 to 0.26)
–0.19 (–0.39 to 0.00)
0.04 (–0.55 to 0.63)
–0.09 (–0.22 to 0.03)
Schwartz et al. 1995
Alexander et al. 1998
Sakai et al. 2000
Lee SS et al. 2001
Kim et al. 2004
Wu et al. 2004
Overall
11.7
6.6
10.1
27.6
39.7
4.3
100.0
–1 1 0
Figure 2. Random-effect WMD and 95% CI in blood lead level between ALAD1-2/2-2 and ALAD1-1 carriers. 
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[g/dL (95% CI)]
–0.10 (–0.86 to 0.66)
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0.05 (–0.79 to 0.88)
7.60 (5.01 to 10.19)
5.50 (–1.39 to 12.39)
7.34 (4.92 to 9.76)
8.60 (2.57 to 14.63)
1.50 (–4.54 to 7.54)
2.33 (0.05 to 4.61)
5.30 (–0.30 to 10.90)
2.50 (–1.17 to 6.17)
1.00 (–7.22 to 9.22)
0.50 (–6.00 to 7.00)
3.50 (–4.37 to 11.37)
1.70 (–0.96 to 4.36)
2.56 (1.21 to 3.90)
2.31 (0.93 to 3.70)
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Environmental, adults
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Wetmur et al. 1991a
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Wetmur et al. 1991a
Schwartz et al. 1995
Fleming et al. 1998
Alexander et al. 1998
Schwartz et al. 2000
Sakai et al. 2000
Suzen et al. 2003
Wu et al. 2004
Kim et al. 2004
Subtotal
Overall
Weight (%)
13.8
12.4
13.7
39.9
9.6
3.2
12.8
3.9
3.9
10.4
4.3
7.2
2.4
3.5
2.6
9.4
47.4
100.0
–14.634 14.6341 0
WMDThese data indicate that the bioavailability of
lead is greater in ALAD1-1 individuals than in
ALAD1-2 individuals. 
ALAD polymorphism and kidney func-
tion. Serum creatinine. Four studies reported
serum creatinine values and ALAD polymor-
phism (Bergdahl et al. 1997a; Smith et al.
1995; Weaver et al. 2003; Wu et al. 2003).
The study by Bergdahl et al. (1997a) was
excluded because it was not possible to calcu-
late the mean and SD. Therefore, only three
studies were analyzed by pooled SMD: two
conducted in environmentally exposed indi-
viduals (Smith et al. 1995; Wu et al. 2003),
and one in lead-exposed workers (Weaver
et al. 2003). Very high heterogeneity was pres-
ent (p < 0.001; I 2 = 92.9% ) (Table 4), that
could be attributed to different levels of lead
exposure. Pooled analysis of the two studies
reporting low levels of lead exposure (environ-
mental studies) shows that individuals carrying
the ALAD2 allele had a corresponding signiﬁ-
cantly higher serum creatinine (SMD = 0.48;
95% CI, 0.33 to 0.62) than those individuals
homozygous for ALAD1.
ALAD polymorphism and blood pressure.
Two cross-sectional studies related systolic
blood pressure to ALAD polymorphism (Lee
BK et al. 2001; Smith et al. 1995). The
pooled WMD was 0.30 mmHg higher in
individuals carrying the ALAD2 allele, but the
difference was not statistically significant
(95% CI, –2.18 to 2.78) (Table 4).
Heterogeneity was present among three
studies (Lee BK et al. 2001; Smith et al. 1995;
Wu et al. 2003) relating diastolic blood pres-
sure to ALAD polymorphism (χ2
2 = 6.16; p =
0.05; I2 = 66.9%) (Table 4). This heterogene-
ity was most likely due to the different fre-
quency of the ALAD2 allele in the population
investigated, as well as the level of lead expo-
sure. Exclusion of the occupational study (Lee
BK et al. 2001), which has a low frequency of
ALAD2 allele and modestly higher levels of
lead exposure, resulted in a nonsigniﬁcant test
for heterogeneity (χ2
1 = 0.47, p = 0.49), a sig-
niﬁcant pooled WMD that was 1.88 mmHg
higher in individuals carrying the ALAD2 allele
(95% CI, 0.46 to 3.31; p = 0.01) (Table 4). 
Discussion
Our goal in this study was to determine the
associations of ALAD polymorphism on blood
lead levels and bone deposition, and the role of
this polymorphism as a modifier of target
organ lead toxicity. Overall, our meta-analysis
shows that individuals carrying the ALAD2
allele had generally higher blood lead levels
than those homozygous for ALAD1. The data
suggest that carrying the ALAD allele is a sig-
niﬁcant determinant for blood lead concentra-
tions among individuals subjected to high
levels, such as lead-exposed workers. ALAD2
does not appear to be a signiﬁcant determinant
of blood lead concentrations among adult
individuals exposed to relatively low lead levels
(< 10 μg/dL).
The biologic plausibility for a differential
role of the two ALAD alleles lies in the fact
that the ALAD2 enzyme could potentially
have a higher affinity and stability for lead
than ALAD1. Among lead workers, carriers of
the ALAD2 allele had a higher percentage of
lead bound to the ALAD enzyme compared
to ALAD1 homozygotes (Bergdahl et al.
1997b). The higher percentage of lead bound
to the ALAD 2 enzyme translates to lower
levels of bioavailable lead; the reverse is true
in ALAD1 homozygotes. This is consistent
with our results. We found that people carry-
ing the ALAD2 allele had a weighted average
of 21.30 μg lower DMSA-chelatable lead
than individuals lacking the allele. 
The insertion of ferrous iron (Fe2+) into
the porphyrin ring to form heme is catalyzed
by the mitochondrial enzyme ferrochelatase,
which shows reduced activity in the presence
of lead (Ponka 1997).This reduction in fer-
rochelatase activity frees protoporphyrin to
accept zinc, resulting in the formation of zinc
protophorphyrin, which is characteristically
increased in both lead poisoning and iron
deﬁciency. 
The increased amount of lead bound to the
ALAD 2 isozyme should result in decreased
lead available to inhibit ferrochelatase, which
would thus be available to catalyze the forma-
tion of heme with subsequent formation of
ALAD polymorphism and lead: a meta-analysis
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Table 4. Summary effect size between ALAD1-2/2-2 and ALAD1-1 carriers on various outcomes.
Publication bias 
Heterogeneity tests (p-value)
χ2 test Begg 
No. (type) of studies SMD 95% CI p-value I2 (%) (corrected) Egger
Cortical (tibia) lead 4 (Combined) –0.07 –0.20 to 0.05 0.59 0.0 1.00 0.64
2 (Occupational) –0.07 –0.28 to 0.14 0.23
2 (Environmental) –0.07 –0.26 to 0.11 0.50
Trabecular lead (patella  4 (Combined) –0.03 –0.16 to 0.09 0.60 0.0 0.09 0.03
and calcaneus) 2 (Occupational) –0.03 –0.21 to 0.15 0.68
2 (Environmental) 0.01 –0.30 to 0.31 0.19
Difference 3  (Combined) 0.03 –0.21 to 0.26 0.13 50.9 0.30 0.23
trabecular–cortical 1 (Occupational) –0.07 –0.33 to 0.19
2 (Environmental) 0.14 –0.35 to 0.64
DMSA-chelatable lead 2 (Occupational)  –21.30a –40.81 to –1.79a 0.85 0.0
Serum creatinine 3 (Combined) 0.23 –0.24 to 0.70 0.00 92.9 1.00 0.38
1 (Occupational)  –0.27 –0.50 to –0.04
2 (Environmental) 0.48 0.33 to 0.62
Systolic blood pressure  2 (Combined) 0.30a –2.18 to 2.78a 0.33 — 1.00 —
1 (Occupational)  –1.10a –4.84 to 2.64a
1 (Environmental) 1.40a –1.92 to 4.72a
Diastolic blood pressure 3 (Combined)  0.81a –1.47 to 3.09a 0.05 66.9 1.00 0.24
1 (Occupational) –2.00a –4.89 to 0.89a
2 (Environmental) 1.88a 0.46 to 3.31a
aWMD.
Figure 4. Random-effect WMD in hemoglobin values between ALAD1-2/2-2 and ALAD1-1 carriers. 
0.15 (–0.41 to 0.71)
0.30 (–0.32 to 0.92)
0.22 (–0.20 to 0.63)
0.30 (–0.22 to 0.82)
0.00 (–0.37 to 0.37)
0.20 (0.04 to 0.36)
–0.10 (–1.30 to 1.10)
0.17 (0.04 to 0.31)
0.18 (0.05 to 0.31)
Environmental, adults
Hsieh et al. 2000
Perez-Bravo et al. 2004
Subtotal
Occupational
Schwartz et al. 1997a
Schwartz et al. 2000
Kim et al. 2004
Wu et al. 2004
Subtotal
Overall
5.4
4.5
9.9
6.2
12.7
69.9
1.2
90.1
100.0
WMD
 [g/dL (95% CI]
Study
Weight (%)
–1.3047 1.30471 0
WMDhemoglobin in the presence of Fe2+. In
contrast, the weaker binding of lead to ALAD1
results in more bioavailable lead that can
inhibit ferrochelatase. This results in increased
formation of ZPP and decreased production of
heme and hemoglobin. 
Our meta-analysis supports these modify-
ing effects of the ALAD2 allele. Hemoglobin
level was 0.18 g/dL (95% CI, 0.05 to 0.31)
higher in lead workers with the ALAD1-2
genotype. Although ALAD2 carriers had a
lower ZPP (SMD = –0.10), the difference was
not statistically signiﬁcant. ZPP is characteris-
tically increased in lead poisoning and starts to
rise exponentially only at blood lead concen-
trations > 30 μg/dL in adults or > 25 μg/dL in
children (Baldwin and Marshall 1999). It is
thus reasonable to expect a modifying effect
on ZPP by ALAD polymorphism with
increased lead exposure. The absence of a sig-
nificant effect could be due to differences in
exposure levels to the toxicant across the study
populations. Schwartz et al. (1995) found that
workers carrying the ALAD2 allele in the plant
with the highest lead exposures were associated
with lower ZPP measurements. The associa-
tion of ALAD2 with lower ZPP was also
reported by Alexander et al. (1998), and this
association was more pronounced in workers
with blood lead concentrations ≥ 40 μg/dL.
Significantly higher levels of ZPP were
reported in ALAD1 homozygous Japanese lead
workers compared with ALAD2 carriers at
BLLs > 20 μg/dL (Sakai et al. 2000). Overall,
these studies indicate that the ALAD allele is a
modifying factor in the formation of ZPP at
higher blood lead levels (> 20 μg/dL), and that
ALAD2 carriers exhibit lower levels of ZPP
and higher levels of hemoglobin.
Differences in lead accumulation in various
bone types have been reported. Tibia concen-
trations differ from those observed in the
patella. The cortical bone of the tibia repre-
sents a long-term storage depot with an elimi-
nation half-life for lead in excess of a decade.
ALAD status may modify the way in which
lead partitions between these bone depots
(Smith et al. 1995). That is, the variant
ALAD2 protein may effectively increase the
blood and soft tissue (e.g., spleen and kidney)
compartment half-lives of lead, thus decreasing
partitioning to the cortical bone compartment.
Our meta-analysis did not find a significant
association between ALAD polymorphism and
accumulation of lead in the different bone
compartments. More recently, emphasis has
focused on the role of vitamin D receptor
(VDR) polymorphism in modulating the lead
level in the bone compartment (Schwartz et al.
2000; Theppeang et al. 2004). The vitamin D
endocrine system plays an essential role in cal-
cium homeostasis and bone metabolism.
Vitamin D is a prohormone that is metaboli-
cally converted to the active metabolite
1,25-dihydroxyvitamin D (calcitriol), which
facilitates calcium absorption from the gut and
directly stimulates osteoblasts, the bone-form-
ing cells. These effects are mediated through
activation of the VDR, which alters the tran-
scription rates of target genes responsible for
the biological response (Dusso et al. 2005).
Lead is a divalent cation that behaves like cal-
cium in biological systems, and interactions
between lead and calcium have been reported.
Calcium and calcitriol deficiencies result in
increased lead absorption from the gut
(Fullmer 1990). Conversely, higher dietary cal-
cium intake results in lower BLLs in children
(Mahaffey et al. 1986) and in reduced bone
lead accumulation in animals (Bogden et al.
1995). VDR polymorphism may thus influ-
ence lead uptake and retention in bone storage
pools. Theppeang et al. (2004) found a signiﬁ-
cantly higher patella lead burden in lead work-
ers carrying the VDR B allele. Schwartz et al.
(2000) previously reported in adjusted analyses
that lead workers carrying the VDR B allele
had significantly higher tibia lead levels (on
average 6.4 μg/g) than workers with the
VDR bb genotype. 
Associations of ALAD polymorphism and
renal effects of lead exposure have also been
reported. Smith et al. (1995) found that the
ALAD2 carriers were more susceptible to
decrements in renal function as measured by
increases in serum creatinine and blood urea
nitrogen (BUN). The increased serum creati-
nine in individuals carrying ALAD2 was
confirmed in a sample of 89 lead workers
(Bergdahl et al. 1997a). Conversely, Korean
lead workers with the ALAD1-2 genotype
exhibited lower BUN and serum creatinine
(Weaver et al. 2003).The pooled SMD in our
meta-analysis showed higher serum creatinine
values among ALAD2 carriers. However, there
was signiﬁcant heterogeneity among the stud-
ies that might be ascribed to the level of lead
exposure, frequency of the polymorphism in
the population investigated, and other possible
confounders (e.g., age, sex). Pooled analysis of
the studies reporting low levels of lead expo-
sure (environmental studies) shows that indi-
viduals carrying the ALAD2 allele had a
corresponding statistically significant mean
average of 0.10 mg/dL higher serum creati-
nine than those individuals homozygous for
ALAD1.
The effect of lead on blood pressure has
also been widely investigated (Kopp et al.
1988; Pirkle et al. 1985). The available litera-
ture suggests that there is a positive, albeit
weak association between systolic blood pres-
sure and blood lead concentration. A recent
meta-analysis showed that a 2-fold increase in
blood lead concentration is associated with a
rise in systolic pressure of 1.0 mmHg (95%
CI, 0.5 to 1.4; p < 0.001) and an increase in
diastolic pressure of 0.6 mmHg (95% CI,
0.4 to 0.8; p < 0.001) (Nawrot et al. 2002).
Our meta-analysis did not ﬁnd a difference in
systolic blood pressure associated with ALAD
polymorphism. However, individuals carrying
the ALAD2 allele who were environmentally
exposed to lead showed an increase in diastolic
blood pressure of 1.88 mmHg. 
The biological plausibility of a causal rela-
tionship between elevated blood pressure and
lead exposure has been studied mainly in ani-
mals and in vitro. Experiments have demon-
strated that lead affects the smooth muscles of
blood vessels by interfering with the Na+/K+-
pump, cyclic AMP, calcium ions (Ca2+), and
the rennin–angiotensin system (McAllister
et al. 1971; Roels et al. 1990; Sandstead et al.
1970). In this context, the presence of other
polymorphic genes, such as that coding for
endothelial nitric oxide synthase (eNOS),
may play an additional role. Endothelial NOS
converts L-arginine into nitric oxide, causing
relaxation of vascular smooth muscle (Vaziri
and Ding 2001; Vaziri et al. 1999) and asso-
ciations among eNOS genotypes, hyperten-
sion, lead exposure, and intracellular Ca2+
concentrations have been reported (Colombo
et al. 2002; Sofowora et al. 2001). 
Conclusions
Measurement of blood lead level is the most
convenient, readily available, and logistically
feasible biomarker for assessing risk of lead
toxicity. However, the presence of the ALAD2
allele may obscure the clinical interpretation of
blood lead values in terms of target organ toxi-
city. ALAD2 carriers generally show higher
BLLs in adults at increased levels of lead expo-
sure, and appear to be protected against
adverse hemapoietic effects as measured by
hemoglobin levels. The modifying effects of
ALAD on other organs remain unclear, partly
because of the the small number of studies.
These numbers are relatively small and there-
fore any inferences have to be cautious
(Ioannidis et al. 2003). The strength of the
present analysis, however, is based on the
aggregation of published studies, thus there is
more information for investigating the effect
of the allele under investigation. Moreover,
the role of other genes such as VDR could alter
lead deposition in bone. The increasing appli-
cation of molecular epidemiologic methods
has emphasized the interaction between genes
and the environment. Multiple gene polymor-
phisms suggest that genes having a small effect
may interact to determine the overall risk.
This meta-analysis identifies several issues:
a) there are numerous potential sources of het-
erogeneity, including varying allele frequencies
and HWE in the populations; b) in the con-
text of gene-environment interactions, gene–
gene interactions may play a role (for example,
ALAD, VDR, and eNOS may interact to
modify lead levels in several organs). 
Scinicariello et al.
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